Inhibitory Effects of Talipexole and Pramipexole on MPTP-Induced Dopamine Reduction in the Striatum of C57BL/6N Mice

We have investigated the effects of two novel antiparkinsonian drugs, talipexole (Domin®)and pramipexole, on MPTP-induced dopamine (DA)reduction in the striatum of C57BL/6N mice in comparison with those of bromocriptine. Fifteen days after MPTP treatment (25 mg/kg, i.p., given daily for 5 days), the...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of pharmacology Vol. 74; no. 1; pp. 51 - 57
Main Authors Kitamura, Yoshihisa, Kohno, Yasuko, Nakazawa, Minako, Nomura, Yasuyuki
Format Journal Article
LanguageEnglish
Published The Japanese Pharmacological Society 1997
Subjects
Antiparkinsonian drug
MPTP
Neuroprotective effect
Pramipexole
Talipexole
Online AccessGet full text

Cover

More Information
Summary:We have investigated the effects of two novel antiparkinsonian drugs, talipexole (Domin®)and pramipexole, on MPTP-induced dopamine (DA)reduction in the striatum of C57BL/6N mice in comparison with those of bromocriptine. Fifteen days after MPTP treatment (25 mg/kg, i.p., given daily for 5 days), the DA content in the striatum was decreased to 40-60010 of the control value. Among the three dopamine receptor agonists, talipexole and pramipexole (1 mg/kg, i.p., once a day for 20 days)more significantly suppressed the MPTP-induced DA reduction in the striatum than bromocriptine (10 mg/kg, i.p., once a day for 20 days). Talipexole did not influence [3H]MPP+ uptake into striatal synaptosomes. These results suggest that talipexole and pramipexole have a protective effect against MPTP-induced DA reduction in the striatum of C57BL/6N mice.
ISSN:0021-5198
1347-3506
DOI:10.1254/jjp.74.51